Skip to main content

Table 1 Eligibility criteria

From: Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study

Inclusion criteria

Exclusion criteria

Diagnosis of MCI due to AD or AD dementia based on patient history, neuropsychological assessment, and neuroimaging within the last 2 years

Meeting the additional criteria of a non-AD neurodegenerative disease (vascular co-pathology is permitted)

Presence of NPS; ≥ 1 symptoms on NPI-Q

Legally incapable to give informed consent

MMSE score > 15

Evidence of current delirium or previous delirium

Patients need to be community-dwelling

Primary (premorbid) psychiatric disorders that could better explain the manifestation of NPS

Availability of a reliable informant

Participating in a clinical (medication) trial

  1. MCI mild cognitive impairment, AD Alzheimer’s disease, NPS neuropsychiatric symptoms, NPI-Q Neuropsychiatric Inventory Questionnaire, MMSE Mini-Mental State Examination